Aktiia Secures $42M for Blood Pressure Intelligence Platform, Rebrands to Hilo

What You Should Know:

–  Aktiia, a blood pressure intelligence platform, announces an oversubscribed $42 million Series B funding round, co-led by Earlybird Health and Wellington Partners, with new investors Kfund and NaturalX Health Ventures, and participation from existing investors redalpine, Khosla Ventures, Molten Ventures, Translink Capital and Verve Ventures.

– The investment, which has brought the total financing to date above $100 million, will accelerate the company’s mission to manage the world’s blood pressure. 

Hilo Secures Series B Funding to Advance Cuffless Blood Pressure Monitoring Technology and Global Expansion

Hilo, formerly known as Aktiia, has announced the close of its Series B funding round, marking a significant milestone in its journey to revolutionize blood pressure monitoring. This funding will drive product innovation, accelerate international expansion, and support the development of its enterprise-focused blood pressure intelligence platform.

The latest investment builds on a period of rapid progress for the company, during which it has:

• Achieved 76% compounded annual revenue growth
• Secured CE marking for its mobile phone camera-based blood pressure monitoring technology
• Gained regulatory approvals in Canada, Australia, and Saudi Arabia
• Completed a pivotal clinical trial in preparation for its U.S. FDA application

As part of this next phase of growth, the company has introduced a new brand identity—Hilo—reflecting its global ambition to make cuffless, clinically validated blood pressure monitoring universally accessible and effortless. This rebrand marks a strategic evolution, aligning with Hilo’s vision of enabling healthier blood pressure for all, while continuing to deliver the trusted technology and clinically relevant reporting for which the company is known.

To date, Hilo has sold over 120,000 devices and established itself as a leader in the emerging cuffless blood pressure monitoring (CBPM) category. Its proprietary foundation machine learning model is specifically trained for blood pressure assessment, drawing on:

• Tens of billions of optical signals from real-world users
• Hundreds of millions of calibration points to ensure precision and reliability

Commenting on the announcement, Hilo CEO Raghav “Rags” Gupta emphasized that the Series B round affirms investor confidence in Hilo’s technology and mission. He noted that with billions of people worldwide affected by hypertension—and only 20% achieving adequate control—the need for more accessible, accurate, and convenient monitoring solutions is urgent. The rebrand to Hilo, he added, represents a broader commitment to global health empowerment through intelligent, user-centered tools.